CSNK1D — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL31361	0.62	14/20
SCHEMBL140467	0.49	12/20
SCHEMBL143821	0.55	8/20
SCHEMBL84220	0.53	7/20
SCHEMBL144035	0.48	7/20
SCHEMBL31425	0.51	6/20
SCHEMBL144028	0.44	6/20
Sb-203580 (SCHEMBL95208)	0.75	5/20
Sb-203580 (SCHEMBL146399)	0.75	5/20
Pd-169316 (SCHEMBL154958)	0.75	5/20
SCHEMBL69095	0.67	5/20
SCHEMBL67376	0.64	5/20
SCHEMBL66923	0.60	5/20
SCHEMBL67192	0.60	5/20
SCHEMBL68165	0.59	5/20
SCHEMBL67174	0.50	5/20
Linifanib (SCHEMBL93804)	1.00	4/20
SCHEMBL178158	0.77	4/20
SCHEMBL68193	0.67	4/20
SCHEMBL147422	0.66	4/20

Clinical trials — most relevant to CSNK1D by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	COMPLETED
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	ACTIVE_NOT_RECRUITING
Doxycycline in Human Pulmonary Tuberculosis	PHASE2	COMPLETED
Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC	PHASE2	COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Evaluating MED2005 & Nitrostat Bioavailability	PHASE1	COMPLETED
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma	PHASE1	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer	EARLY_PHASE1	COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease	nan	UNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies	nan	ENROLLING_BY_INVITATION
Study of Metabolic Modifications in Children With Noonan Syndrome	nan	COMPLETED
Ischemic Preconditioning to Prevent Acute Kidney Injury	nan	COMPLETED
Improving the Diagnosis of Common Variable Immune Deficiency	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Nuclear Myosin VI - a Therapeutic Target in Breast Cancer	nan	UNKNOWN
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults	nan	COMPLETED
Effect of Esterogen Receptor Modulator on Gene in Bipolar Diseas	nan	NOT_YET_RECRUITING
Family Blood Pressure Program - HyperGEN	nan	COMPLETED
IPSC Repository of Pediatric Cardiovascular Disease	nan	RECRUITING
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH)	nan	COMPLETED
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex	nan	COMPLETED
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients	nan	UNKNOWN
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CSNK1D binder may also engage these)

Protein	Name	Similarity
P35508	—	1.000	P35508 →
Q9DC28	—	1.000	Q9DC28 →
Q06486	—	1.000	Q06486 →
Q5RC72	—	1.000	Q5RC72 →
Q6P3K7	—	1.000	Q6P3K7 →
Q6P647	—	1.000	Q6P647 →
Q5BP74	—	1.000	Q5BP74 →
Q7T2E3	—	1.000	Q7T2E3 →
CSNK1E	Casein kinase I isoform epsilon	1.000	landscape →
Q5ZLL1	—	1.000	Q5ZLL1 →
Q9JMK2	—	0.996	Q9JMK2 →
A0A0E0S0W9	—	0.991	A0A0E0S0W9 →
Q62761	—	0.989	Q62761 →
Q62762	—	0.988	Q62762 →
Q8BVP5	—	0.988	Q8BVP5 →
Q39050	—	0.988	Q39050 →
Q8VYK9	—	0.987	Q8VYK9 →
Q9ZUP4	—	0.987	Q9ZUP4 →
G5EI58	—	0.985	G5EI58 →
CSNK1G2	Casein kinase I isoform gamma-2	0.985	landscape →
Q4R9A9	—	0.985	Q4R9A9 →
P42158	—	0.985	P42158 →
Q5PRD4	—	0.984	Q5PRD4 →
Q8BTH8	—	0.983	Q8BTH8 →
Q5ZJS0	—	0.983	Q5ZJS0 →
CSNK1G1	Casein kinase I isoform gamma-1	0.983	landscape →
Q9LSX4	—	0.982	Q9LSX4 →
P40235	—	0.982	P40235 →
Q9ZWB3	—	0.982	Q9ZWB3 →
Q93Z18	—	0.982	Q93Z18 →